吡格列酮作为一种过氧化物酶体增殖激活受体γ（peroxisome proliferator-activated receptor γ，PPARγ）的激动剂，可能参与糖脂代谢、氧化应激、免疫炎症反应的调节，从而起到改善抑郁的作用。研究发现，吡格列酮对抑郁症尤其是治疗抵抗和共病代谢综合征的患者疗效较好，有望成为抑郁症治疗的新方案。该文综述吡格列酮在抑郁症临床应用及相关机制的研究进展，以期为后续研究提供理论依据和支持。

As an agonist of peroxisome proliferator-activated receptor γ (PPARγ), pioglitazone may be involved in the regulation of glycolipid metabolism, oxidative stress and immune inflammatory response, thereby improving depression. Studies find that pioglitazone is effective in treating depression, especially in patients with resistance and comorbid metabolic syndrome, and is expected to be a new treatment for depression. This article reviews the research progress of pioglitazone in clinical application and related mechanisms of depression, into provide theoretical basis and support for subsequent research.